Temozolomide-induced severe myelosuppression: Analysis of clinically associated polymorphisms in two patients

Anti-Cancer Drugs

Volumn 22, Issue 1, 2011, Pages 104-110

  Sylvester, Robert K ^a   Steen, Preston ^b   Tate, John M ^c   Mehta, Minesh ^d   Petrich, Ryan J ^a   Berg, Alexander ^a   Kolesar, Jill ^d  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b Roger Maris Cancer Center   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

epigenetic silencing; glioblastoma; multidrug resistance gene; myelosuppression; O6 methylguanine DNA methyltransferase polymorphism; temozolomide

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; DEXAMETHASONE; ETIRACETAM; FAMOTIDINE; GENOMIC DNA; GLUTATHIONE TRANSFERASE P1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE;

ADULT; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DNA EXTRACTION; EPIGENETICS; FEMALE; GENE; GENE SILENCING; GENOTYPE; HETEROZYGOSITY; HUMAN; LABORATORY TEST; MALE; MISSENSE MUTATION; NECROTIZING FASCIITIS; NEUTROPENIA; NQ01 GENE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RADIATION DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; FEMALE; GLIOMA; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS, NEUROEPITHELIAL; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; P-GLYCOPROTEIN; PATIENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 78650517653     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283407e9f     Document Type: Article

References (28)

1. Stupp R, Mason WP, Van den Bent MJ,Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
2. Stupp R, Hegi ME, Mason WP, Van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-466.
3. Singhal N, Selva-Nayagam S, Brown MP. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment: Case study and review of literature. J Neurooncol 2007; 85:229-230.
4. Jalali R, Singh P, Menon H, Gujral S. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide. J Neurooncol 2007; 85:105-107.
5. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, Van Besien K. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 2006; 7:436-438.
6. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88:1004-1011.
7. Middleton MR, Lee SM, Arance A, Wood M, Thatcher N, Margison GP. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study. Int J Cancer 2000; 88:469-473.
8. Sabharwal A, Waters R, Danson S, Clamp A, Iorigan P, Thatcher N, et al. Predicting the myelotoxicity of chemotherapy: The use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res 2009; [E-pub ahead of print].
9. Pegg AE, Fang Q, Loktionova NA. Human variants of O6-alkylguanine-DNA alkyltransferase. DNA Repair (Amst) 2007; 6:1071-1078.
10. Bugni JM, Han J, Tsai M, Hunter DJ, Samson LD. Genetic association and functional studies of major polymorphic variants of MGMT. DNA Repair (Amst) 2007; 6:1116-1126.
11. Sabharwal A, Middleton MR. Exploiting the role of O6-methylguanine- DNAmethyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol 2006; 6:355-363.
12. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20:2388-2399.
13. Liu L, Gerson SL. Targeted modulation of MGMT: Clinical implications. Clin Cancer Res 2006; 12:328-331.
14. Hegi ME, Liu L, Herman JG, Stupp R,WickW,Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26:4189-4199.
15. Hau P, Stupp R, Hegi ME. MGMT methylation status: The advent of stratified therapy in glioblastoma? Dis Markers 2007; 23:97-104.
16. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009; 101:124-131.
17. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, et al. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res 2006; 12:4738-4746.
18. Nagane M, Nozue K, Shimizu S, Waha A, Miyazaki H, Kurita H, et al. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma-analysis of O6-methylguanine-DNA methyltransferase status. J Neurooncol 2009; 92:227-232.
19. Armstrong TS, Cao Y, Scheurer ME, Vera-Bolanos E, Manning R, Okcu MF, et al. Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors. Neuro Oncol 2009; 11:825-832.
20. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25:231-259.
21. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 2009; 20:175-181.
22. Van Tellingen O, Buckle T, Jonker JW, Van der Valk MA, Beijnen JH. P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br J Cancer 2003; 89:1776-1782.
23. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008; 99:967-972.
24. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62:4955-4962.
25. Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, et al. O6- methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 2003; 89:1517-1523.
26. Margison GP, Heighway J, Pearson S, McGown G, Thorncroft MR,Watson AJ, et al. Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells. Carcinogenesis 2005; 26:1473-1480.
27. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449:851-861.
28. Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 1998; 8:1229-1231.